Form 4: ImmunityBio Director Trades Under 10b5-1 Plan

ImmunityBio Director Christobel Selecky executed a series of stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Christobel Selecky acquired and disposed of common stock of ImmunityBio, Inc. (IBRX) on June 29 and June 30, 2026.
• Transactions involved the exercise of stock options at prices ranging from $2.84 to $2.99 per share.
• A total of 95,722 shares were sold on June 29, 2026, at a weighted average price of $9.00 to $9.08.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were conducted under a pre-established plan, but the sale of a significant number of shares by a director warrants attention.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impactful trading.
• The exercise prices of the options were significantly lower than the sale prices, indicating profitable transactions for the reporting person.

Negatives

• A significant number of shares were sold by a director, which could be perceived negatively by the market.
• The filing details the disposal of all directly held common stock by the reporting person.

Risks

• Potential for negative market perception due to a director selling a substantial number of shares.
• The Rule 10b5-1 plan implies a strategy to sell shares over time, which could continue.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
• Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person.
• The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to diversify holdings or manage personal finances while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a director as a potential negative signal, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees: May observe director trading patterns as an indicator of company performance or management confidence.
• Creditors: Unlikely to be directly impacted by this type of transaction.

Next Steps

• The reporting person may continue to sell shares under the Rule 10b5-1 plan if it remains active.
• The company may be required to provide further details on specific sale prices upon request from regulatory bodies or shareholders.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Options, Beneficial Ownership, ImmunityBio, IBRX, Director Transactions